The synergy of linagliptin and empagliflozin in catering to diabetes mellitus in Pakistan Authors Ainan Arshad Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan Kashif Khan Aga Khan University School of Nursing and Midwifery, Karachi, Pakistan Muhammad Shoaib Aga Khan University School of Nursing and Midwifery, Karachi, Pakistan DOI: https://doi.org/10.47391/JPMA.11145 Keywords: Diabetes, Linagliptin, Empagliflozin, Combination therapy, Pakistan Abstract Diabetes is rapidly increasing globally, especially in low- and middle-income countries, with Pakistan ranking third in prevalence, having 33 million people. The lack of adherence to the first-line treatment, metformin, mainly due to gastrointestinal side effects, is a significant concern. A novel approach for managing type 2 diabetes in Pakistan is to combine linagliptin and empagliflozin. Linagliptin is well-tolerated and suitable for those who cannot tolerate metformin, while empagliflozin reduces cardiovascular risks and nephropathy, showing promising results in controlling diabetes with minimal side effects. The synergy between linagliptin and empagliflozin could greatly improve diabetes management and patient wellbeing. It is recommended that healthcare providers in Pakistan use social media and seminars to educate the public on this new treatment option to tackle the diabetes crisis effectively. Key Words: Diabetes, Linagliptin, Empagliflozin, Combination therapy, Pakistan. Downloads Full Text Article Published 2025-01-26 How to Cite Ainan Arshad, Kashif Khan, & Muhammad Shoaib. (2025). The synergy of linagliptin and empagliflozin in catering to diabetes mellitus in Pakistan. Journal of the Pakistan Medical Association, 75(02), 284–286. https://doi.org/10.47391/JPMA.11145 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Issue Vol. 75 No. 02 (2025): FEBRUARY Section SHORT REPORT License Copyright (c) 2025 Journal of the Pakistan Medical Association This work is licensed under a Creative Commons Attribution 4.0 International License.